NCT06916013Not yet recruiting
Focal Laser Ablation in Prostate Cancer
Transperineal Targeted Focal Laser Ablation of Localized Intermediate Risk Prostatic Adenocarcinoma (Pilot Study)
Source: ClinicalTrials.gov · Last updated 8 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To assess the effectiveness of MRI-US or PSMA PET/CT-U/S fusion-guided focal laser ablation (FLA) for the treatment of a localized, intermediate-risk prostate cancer in terms of short-term oncological \& functional outcomes.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 14 Feb 2025
- Start date
- Apr 2025
- Primary completion date
- Apr 2027
- Lead sponsor
- Ain Shams University
- Diseases
- Prostate cancer
- NCT number
- NCT06916013
What you commit to
- Study type: Observational
- Planned participants: 30
- From Apr 2025 to the primary completion date, Apr 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Prostate cancer invisible on mpMRI or PSMA PET/CT but positive in the systematic biopsies.
- Urinary tract infection (UTI)
- Severe coagulation disorders
- Paramagnetic contrast agent allergy
- Acute and/or chronic renal failure
Other
- Presence of \>2 MRI-visible lesions and positive in the biopsies.
- Extracapsular extension
- Seminal vesicle invasion
- Presence of metastases detected by imaging
- Gleason Score \> 7
- Stage \> T2b
- PSA \> 20 ng/mL
- Severe lower urinary tract symptoms defined as an IPSS \>20
- Inadequate compliance
- Contraindications to MRI
Who the study is looking for
- Prostate cancer visible on mpMRI or PSMA PET/CT and positive in the targeted biopsy.
- Gleason score 7 (ISUP grade 2/3)
- PSA 10-20 ng/mL
- Clinical stage T2b
- Refusing radical prostatectomy.
Age in the registry: 45 years to - · Sex: Male · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.